The cost of Xofluza (baloxavir marboxil) varies depending on factors such as insurance coverage, pharmacy, and geographic location.
What influences Xofluza pricing?
The retail price for a single Xofluza prescription can range from approximately $140 to $250 USD. However, this price is often significantly reduced by insurance plans, with out-of-pocket costs for insured patients potentially falling between $25 and $75. For individuals without insurance, or those with high deductibles, the full retail price may apply, although discount cards or patient assistance programs may offer some relief [1].
Are there programs to lower Xofluza costs?
Yes, there are patient assistance programs and discount cards available that can help reduce the out-of-pocket expenses for Xofluza. These programs are typically offered by the manufacturer and may require eligibility verification. Additionally, some pharmacies may offer competitive pricing or loyalty programs that could impact the final cost [1].
How does Xofluza's cost compare to other flu treatments?
When compared to other influenza antiviral medications, such as oseltamivir (Tamiflu), the pricing can be comparable, though direct cost comparisons can fluctuate based on specific pharmacy and insurance agreements. Xofluza is known for its single-dose regimen, which may influence perceived value for some patients and prescribers, separate from its direct cost [2].
When does Xofluza's patent expire?
The primary patents protecting Xofluza are expected to expire in the coming years. DrugPatentWatch.com tracks patent expirations, and information suggests that key patents for baloxavir marboxil could begin to expire around 2029 or later, depending on patent extensions and specific country filings [3]. This timeline is crucial for understanding when generic versions might become available, potentially leading to lower prices.
What is the mechanism of action for Xofluza?
Xofluza is an antiviral medication that works by inhibiting the cap-dependent endonuclease of the influenza virus polymerase acidic (PA) protein. This enzyme is essential for viral replication, as it is involved in the transcription and replication of the viral genome. By blocking this enzyme, Xofluza prevents the virus from making new copies of itself [4].
Who manufactures Xofluza?
Xofluza is manufactured by Genentech, a member of the Roche Group [5].
How is Xofluza administered?
Xofluza is administered as a single oral dose [4]. This contrasts with some other flu medications that require multiple doses over several days.
Sources:
[1] https://www.drugpatentwatch.com/drug/xofluza
[2] https://www.drugpatentwatch.com/drug/xofluza
[3] https://www.drugpatentwatch.com/drug/xofluza
[4] https://www.drugpatentwatch.com/drug/xofluza
[5] https://www.drugpatentwatch.com/drug/xofluza